相似文献
1
Baricitinib set to join the Covid-19 therapeutic arsenal?巴瑞替尼会加入新冠治疗药物库吗？
Rheumatology (Oxford). 2021 Apr 6;60(4):1585-1587. doi: 10.1093/rheumatology/keab061.
2
Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.巴利昔替尼的作用机制支持人工智能预测在 COVID-19 患者中的检测。
EMBO Mol Med. 2020 Aug 7;12(8):e12697. doi: 10.15252/emmm.202012697. Epub 2020 Jun 24.
3
Baricitinib: From Rheumatoid Arthritis to COVID-19.巴瑞替尼：从类风湿关节炎到 COVID-19。
J Clin Pharmacol. 2021 Oct;61(10):1274-1285. doi: 10.1002/jcph.1874. Epub 2021 Jun 12.
4
Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features.COVID-19 治疗的免疫调节剂：可能的作用机制和免疫病理学特征。
Mol Cell Biochem. 2022 Mar;477(3):711-726. doi: 10.1007/s11010-021-04325-9. Epub 2022 Jan 11.
5
JAK inhibition during the early phase of SARS-CoV-2 infection worsens kidney injury by suppressing endogenous antiviral activity in mice.在 SARS-CoV-2 感染的早期阶段抑制 JAK 会通过抑制内源性抗病毒活性而使小鼠的肾脏损伤恶化。
Am J Physiol Renal Physiol. 2024 Jun 1;326(6):F931-F941. doi: 10.1152/ajprenal.00011.2024. Epub 2024 Apr 18.
6
JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality.JAK 抑制可降低 SARS-CoV-2 的肝脏感染性，并调节炎症反应，从而降低发病率和死亡率。
Sci Adv. 2021 Jan 1;7(1). doi: 10.1126/sciadv.abe4724. Print 2021 Jan.
7
Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID-19.巴瑞替尼：关于COVID-19的药理学、安全性及新出现临床经验的综述
Pharmacotherapy. 2020 Aug;40(8):843-856. doi: 10.1002/phar.2438. Epub 2020 Jul 27.
8
The effect of drugs used in rheumatology for treating SARS-CoV2 infection.风湿病药物治疗 SARS-CoV2 感染的效果。
Expert Opin Biol Ther. 2021 Feb;21(2):219-228. doi: 10.1080/14712598.2020.1817372. Epub 2020 Sep 18.
9
Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.巴瑞替尼，一种具有潜在作用的药物，可以阻止 SARS-COV-2 进入靶细胞，并控制由 COVID-19 引起的细胞因子风暴。
Int Immunopharmacol. 2020 Sep;86:106749. doi: 10.1016/j.intimp.2020.106749. Epub 2020 Jul 1.
10
Comment on: Gudu T, Stober C, Cope AP et al. Baricitinib set to join the Covid-19 therapeutic arsenal?评论：古杜·T、斯托伯·C、科普·AP等人。巴瑞替尼即将加入新冠治疗武器库？
Rheumatology (Oxford). 2021 Oct 2;60(10):e371. doi: 10.1093/rheumatology/keab386.
引用本文的文献
1
A narrative review on tofacitinib: The properties, function, and usefulness to treat coronavirus disease 2019.托法替布的叙述性综述：其特性、功能及对治疗2019冠状病毒病的效用
Int J Crit Illn Inj Sci. 2023 Oct-Dec;13(4):192-198. doi: 10.4103/ijciis.ijciis_27_23. Epub 2023 Dec 26.
2
Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial.巴瑞替尼或瑞维鲁单抗治疗成人重症 COVID-19 患者的疗效和安全性（TACTIC-R）：一项随机、平行臂、开放标签、四期临床试验。
Lancet Respir Med. 2023 Dec;11(12):1064-1074. doi: 10.1016/S2213-2600(23)00376-4. Epub 2023 Nov 14.
3
New Applications of JAK/STAT Inhibitors in Pediatrics: Current Use of Ruxolitinib.JAK/STAT抑制剂在儿科的新应用：芦可替尼的当前应用情况
Pharmaceuticals (Basel). 2022 Mar 19;15(3):374. doi: 10.3390/ph15030374.
4
What's new in critical illness and injury science? An evidence-based analysis of the impact of Janus Kinase inhibitors on 28-day mortality in patients admitted with COVID-19.危重症与创伤科学领域有哪些新进展？一项关于Janus激酶抑制剂对COVID-19入院患者28天死亡率影响的循证分析。
Int J Crit Illn Inj Sci. 2021 Jul-Sep;11(3):109-111. doi: 10.4103/ijciis.ijciis_80_21. Epub 2021 Sep 25.
5
Comment on: Gudu T, Stober C, Cope AP et al. Baricitinib set to join the Covid-19 therapeutic arsenal?评论：古杜·T、斯托伯·C、科普·AP等人。巴瑞替尼即将加入新冠治疗武器库？
Rheumatology (Oxford). 2021 Oct 2;60(10):e371. doi: 10.1093/rheumatology/keab386.
本文引用的文献
1
Genetic mechanisms of critical illness in COVID-19.新型冠状病毒肺炎危重症的遗传机制。
Nature. 2021 Mar;591(7848):92-98. doi: 10.1038/s41586-020-03065-y. Epub 2020 Dec 11.
2
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.巴瑞替尼联合瑞德西韦治疗住院的新冠成年患者
N Engl J Med. 2021 Mar 4;384(9):795-807. doi: 10.1056/NEJMoa2031994. Epub 2020 Dec 11.
3
Venous Thromboembolism Risk With JAK Inhibitors: A Meta-Analysis.JAK 抑制剂相关的静脉血栓栓塞风险：一项荟萃分析。
Arthritis Rheumatol. 2021 May;73(5):779-788. doi: 10.1002/art.41580. Epub 2021 Mar 25.
4
Immune asynchrony in COVID-19 pathogenesis and potential immunotherapies.新型冠状病毒肺炎发病机制中的免疫失同步及其潜在免疫治疗策略。
J Exp Med. 2020 Oct 5;217(10). doi: 10.1084/jem.20200674.
5
Dexamethasone in Hospitalized Patients with Covid-19.地塞米松在 COVID-19 住院患者中的应用。
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
6
Repurposed immunomodulatory drugs for Covid-19 in pre-ICu patients - mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 - Repurposed Drugs (TACTIC-R): A structured summary of a study protocol for a randomised controlled trial.用于 ICU 前新冠患者的免疫调节药物再利用 - 新冠 ICU 前住院患者的多臂治疗研究 - 再利用药物（TACTIC-R）：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jul 8;21(1):626. doi: 10.1186/s13063-020-04535-4.
7
Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID-19.巴瑞替尼：关于COVID-19的药理学、安全性及新出现临床经验的综述
Pharmacotherapy. 2020 Aug;40(8):843-856. doi: 10.1002/phar.2438. Epub 2020 Jul 27.
8
Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.巴利昔替尼的作用机制支持人工智能预测在 COVID-19 患者中的检测。
EMBO Mol Med. 2020 Aug 7;12(8):e12697. doi: 10.15252/emmm.202012697. Epub 2020 Jun 24.
9
Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.Janus 激酶抑制剂在炎症性肠病或其他免疫介导性疾病患者中的安全性：系统评价和荟萃分析。
Gastroenterology. 2020 May;158(6):1554-1573.e12. doi: 10.1053/j.gastro.2020.01.001. Epub 2020 Jan 9.
Zotero 插件